Citations

Clear

3030 citation(s) found for "Susan, M".

Outcomes of Mayo Clinic reBoot camps for postimplementation training in the electronic health record
Gordon, Joel , Belford, Sylvia M , Aranguren, Dawn, Fleming, Richard, Gajarawala, Nikunj M., Heiderscheit, Jon, Laabs, Susan, Looft, Kathryn A, Rosedahl, Jordan K., Gordon, Joel E , Aranguren, Dawn L, Blair, David, Laabs, Susan B, Blair, David, Fleming, Richard, O’Horo, John C.

Mayo Clinic

Journal of the American Medical Informatics Association | July 8, 2022 | Volume: 29 | Issue: 9 | Pages: 1518-1524

10.1093/jamia/ocac107 | PMID 35799373 Get It

Abstract Objective After a new electronic health record (EHR) was implemented at Mayo Clinic, a training program called reBoot Camp was created to enhance ongoing education in response to needs identified by physician leaders. Materials and Methods A reBoot camp focused on EHR topics pertinent to ambulatory care was offered from April 2018 through June 2020. There were 37 2-day sessions and 43 1-day sessions, with 673 unique participants. To evaluate outcomes of the reBoot camp, we used survey data to study baseline, immediate, and long-term perceptions of program satisfaction and self-assessed skills with the EHR. The study was conducted among practitioners at a large ambulatory practice network based in several states. Data were collected from April 2018 through January 2021. We analyzed automatically collected metadata and scores that evaluated the amount of personalization and proficiency of use. Results Confidence in skills increased by 13.5 points for general EHR use and was significant in 5 subdomains of use (13–18 point improvement). This degree of user confidence was maintained at the 6-month reassessment. The outcomes of configuration and proficiency scores also improved significantly. Discussion Ongoing education regarding EHR tools is necessary to support continued use of technology. This study was novel because of the amount and breadth of data collected, diversity of user participation, and validation that improvements were maintained over time. Conclusions Participating in a reBoot camp significantly improved user confidence in each domain of the EHR and demonstrated use of best-practice tools. Users maintained gains at the 6-month evaluation phase.
Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
Loftus, Edward V. , Baumgart, Daniel C. , Kinnucan, Jami , Connelly, Susan B. , Salese, Leonardo , Su, Chinyu , Kwok, Kenneth , Woolcott, John , Armuzzi, Alessandro , Kinnucan, Jami A., Loftus, Edward V , Gecse, Krisztina Barbara

Mayo Clinic

Inflammatory Bowel Diseases | July 6, 2022 | Volume: 29 | Issue: 5 | Pages: 744-751

10.1093/ibd/izac139 | PMID 35792493 Get It

Abstract Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Patients with inflammatory bowel disease are susceptible to Clostridium difficile infection (CDI). Here, we evaluate CDI in the tofacitinib UC clinical program. Methods Events from 4 randomized, placebo-controlled studies (phase [P] 2 or P3 induction [NCT00787202; NCT01465763; NCT01458951], P3 maintenance [NCT01458574]) and an open-label, long-term extension (OLE) study (NCT01470612), were analyzed as 3 cohorts: Induction (P2/P3 induction), Maintenance (P3 maintenance), and Overall (patients receiving tofacitinib 5 or 10 mg twice daily [BID] in P2, P3, and OLE studies; including final data from the OLE study, as of August 24, 2020). Proportions and incidence rates (unique patients with events per 100 patient-years of exposure) of CDI were evaluated. Results The overall cohort comprised 1157 patients who received ≥1 dose of tofacitinib 5 or 10 mg BID, with a total of 2814.4 patient-years of tofacitinib exposure and up to 7.8 years of treatment. A total of 82.6% of patients received predominantly tofacitinib 10 mg BID. In the induction, maintenance, and overall cohorts, 3 (2 tofacitinib treated, 1 placebo treated), 3 (all placebo treated), and 9 patients had CDI, respectively; the overall cohort incidence rate was 0.31 (95% confidence interval, 0.14-0.59). CDI were all mild–moderate in severity and resolved with treatment in 8 patients. Six of 9 patients continued tofacitinib treatment without interruption. Two patients had events reported as serious due to hospitalization. Two patients were receiving corticosteroids when the CDI occurred. Conclusion CDIs among patients with UC receiving tofacitinib were infrequent, cases were mild–moderate in severity, and most resolved with treatment.
A rapid response for burnout among inpatient physiatrists: A survey of leaders of inpatient rehabilitation facilities
Farr, Ellen , Lee, Su-Jin , Maltser, Susan , Shapiro, Lauren T. , Verduzco-Gutierrez, Monica , Shapiro, Lauren T , Verduzco‐Gutierrez, Monica

Mayo Clinic

PM&R | July 5, 2022 | Volume: 14 | Issue: 9 | Pages: 1080-1085

10.1002/pmrj.12870 | PMID 35789206 Get It

Abstract Background Symptoms of burnout are highly prevalent among physiatrists, and prior studies have helped identify key contributors to this epidemic of burnout. Little is known about the physician stressors unique to those providing care in inpatient rehabilitation facilities (IRFs) and what strategies such facilities have used to help mitigate burnout among inpatient physiatrists. Objective To identify what IRF leaders perceive as stress points contributing to burnout among inpatient rehabilitation physicians and what, if any, interventions their programs have implemented to help mitigate physician burnout. Design 10 item cross‐sectional survey study of IRF physician and nonphysician leaders in the United States. Participants 104 physicians serving in the roles of IRF medical director, director of rehabilitation, and/or executive leadership and 19 nonphysician IRF leaders. Results Regulatory demands, late admissions, understaffing, and on‐call responsibilities were the major stress points most identified as contributing to physician burnout among both the physician and nonphysician respondents. The use of advanced practice providers and hospitalists were the most common system changes reportedly used to help mitigate physician burnout. Although 57.8% of physician leaders felt late admissions were a major stress point for physicians, only 18.2% of those responding reported having implemented admission cutoff times. Conclusions There are stressors unique to the practice of inpatient rehabilitation that are likely contributing to physiatrist burnout, including late admissions and on‐call responsibilities. Many IRFs have begun to implement system changes to help mitigate burnout among inpatient physiatrists. The use of nonphysiatrist providers is a commonly reported strategy. Future studies are needed to determine the effectiveness of such a strategy on reducing symptoms of burnout among IRF physicians as well as its effect on IRF patient outcomes.
Parallel functional annotation of cancer-associated missense mutations in histone methyltransferases
Cosgrove, Michael S. , Canning, Ashley J., Viggiano, Susan, Fernández-Zapico, Martín E.

Mayo Clinic

No container title available | July 1, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1746399/v1 Get It

Abstract Using exome sequencing for biomarker discovery and precision medicine requires connecting nucleotide-level variation with functional changes in encoded proteins. However, for functionally annotating the thousands of cancer-associated missense mutations, or variants of uncertain significance (VUS), purifying variant proteins for biochemical and functional analysis is cost-prohibitive and inefficient. We describe parallel functional annotation (PFA) of large numbers of VUS using small cultures and crude extracts in 96-well plates. Using members of a histone methyltransferase family, we demonstrate high-throughput structural and functional annotation of cancer-associated mutations. By combining functional annotation of paralogs, we discovered two phylogenetic and clustering parameters that improve the accuracy of sequence-based functional predictions to over 90%. Our results demonstrate the value of PFA for defining oncogenic/tumor suppressor functions of histone methyltransferases as well as enhancing the accuracy of sequence-based algorithms in predicting the effects of cancer-associated mutations.
Traumatic brain injury and post‐traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers
Weiner, Michael W. , Harvey, Danielle , Landau, Susan, Veitch, Dallas P. , Aisen, Paul, Petersen, Ronald C. , Tosun, Duygu , Shaw, Leslie M. , Trojanowski, John Q. , Saykin, Andrew J. , Carli, Charles De, DeCarli, Charles , Tosun, Duygu , DeCarli, Charles , Saykin, Andrew J , Harvey, Danielle J , Tosun, Duygu , Neylan, Thomas C. , Grafman, Jordan Henry , Jack, Clifford R. , Hayes, Jacqueline

Mayo Clinic

Alzheimer's & Dementia | June 29, 2022 | Volume: 19 | Issue: 3 | Pages: 884-895

10.1002/alz.12712 | PMID 35768339 Get It

AbstractIntroductionEpidemiological studies report an association between traumatic brain injury (TBI) and post‐traumatic stress disorder (PTSD) and clinically diagnosed Alzheimer's disease (AD). We examined the association between TBI/PTSD and biomarker‐defined AD.MethodsWe identified 289 non‐demented veterans with TBI and/or PTSD and controls who underwent clinical evaluation, cerebrospinal fluid (CSF) collection, magnetic resonance imaging (MRI), amyloid beta (Aβ) and tau positron emission tomography, and apolipoprotein E testing. Participants were followed for up to 5.2 years.ResultsExposure groups (TBI, PTSD, and TBI + PTSD) had higher prevalence of mild cognitive impairment (MCI: P < .0001) and worse Mini‐Mental State Examination scores (PTSD: P = .008; TBI & PTSD: P = .009) than controls. There were no significant differences in other cognitive scores, MRI volumes, Aβ or tau accumulation, or in most longitudinal measures.DiscussionTBI and/or PTSD were not associated with elevated AD biomarkers. The poorer cognitive status of exposed veterans may be due to other comorbid pathologies.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Arber, Daniel A. , Hasserjian, Robert P. , Borowitz, Michael J., Kvasnicka, Hans Michael , Wang, Sa A. , Bagg, Adam , Barbui, Tiziano , Branford, Susan , Bueso‐Ramos, Carlos E. , Cortes, Jörge E. , Cin, Paola Dal , Dombret, Hervé , Duncavage, Eric J., Ebert, Benjamin L. , Estey, Elihu H. , Foucar, Kathryn , Gangat, Naseema , Gökbuget, Nicola , Hellström‐Lindberg, Eva , Beau, Michelle M. Le , Löwenberg, Bob , Malcovati, Luca , Odenike, Olatoyosi , Papaemmanuil, Elli , Porkka, Kimmo , Radich, Jerald P. , Reiter, Andreas , Rudelius, Martina , Schiffer, Charles A. , Sierra, Jorge , Stone, Richard M. , Tallman, Martin S. , Thiele, Jürgen, Tzankov, Alexandar , Wei, Andrew H. , Weinberg, Olga K. , Wierzbowska, Agnieszka , Cazzola, Mario , Tefferi, Ayalew , Hasserjian, Robert P , Kvasnicka, Hans-Michael , Barbui, Tiziano , Branford, Susan , Cortes, Jorge , DiNardo, Courtney , Ebert, Benjamin L , Gangat, Naseema , Gianelli, Umberto , Hobbs, Gabriela S , Larson, Richard A , Löwenberg, Bob , Macintyre, Elizabeth , Malcovati, Luca , Mullighan, Charles G , Niemeyer, Charlotte Marie , Ogawa, Seishi , Passamonti, Francesco , Porkka, Kimmo , Savona, Michael R , Schmitt-Graeff, Annette , Shimamura, Akiko , Vannucchi, Alessandro M , Vyas, Paresh , Wei, Andrew H , Wierzbowska, Agnieszka , Cazzola, Mario , Döhner, Hartmut , Tzankov, Alexandar , Arber, Daniel A , Orazi, Attilio , Calvo, Katherine R. , DiNardo, Courtney D. , Facchetti, Fabio , Gianelli, Umberto , Godley, Lucy A. , Gotlib, Jason , Hobbs, Gabriela , Hoffman, Ronald , Jabbour, Elias , Kiladjian, Jean‐Jacques , Larson, Richard A. , Loh, Mignon L. , Macintyre, Elizabeth , Mullighan, Charles G. , Órfão, Alberto , Passamonti, Francesco , Pui, Ching-Hon , Rozman, Marı́a , Savona, Michael R. , Stock, Wendy , Tien, Hwei‐Fang , Vannucchi, Alessandro M.

Mayo Clinic

Blood | June 29, 2022 | Volume: 140 | Issue: 11 | Pages: 1200-1228

10.1182/blood.2022015850 | PMID 35767897 Get It

Abstract The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. This collaboration was primarily based on input from a clinical advisory committees (CACs) composed of pathologists, hematologists, oncologists, geneticists, and bioinformaticians from around the world. The recent advances in our understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials have indicated the need for further revising and updating the classification. As a continuation of this CAC-based process, the authors, a group with expertise in the clinical, pathologic, and genetic aspects of these disorders, developed the International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias. Using a multiparameter approach, the main objective of the consensus process was the definition of real disease entities, including the introduction of new entities and refined criteria for existing diagnostic categories, based on accumulated data. The ICC is aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.
Differential migration mechanics and immune responses of glioblastoma subtypes
Shamsan, Ghaidan A. , Liu, Chao J. , Braman, Brooke C , Li, Ruyi , Rathe, Susan K. , Sarver, Aaron L. , Ghaderi, Nima, McMahon, Mariah, Klank, Rebecca, McFarren, S. Joey, Rosato, Pamela C. , Sarkaria, Jann N., Clark, H. Brent , Rosenfeld, Steven S. , Largaespada, David A. , McMahon, Mariah , Shamsan, Ghaidan A , Rosato, Pamela C , Liu, Chao J. , Rathe, Susan K. , Klank, Rebecca L. , Tschida, Barbara R , McFarren, S Joseph. , Masopust, David , Sarkaria, Jann N., Largaespada, David A. , Odde, David J

Mayo Clinic

No container title available | June 29, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2022.06.26.497270 Get It

Abstract Glioblastoma remains a deadly cancer driven in part by invasion of tumor cells into the brain. Transcriptomic analyses have identified distinct molecular subtypes, but mechanistic differences that account for clinical differences are not clear. Here, we show that, as predicted by the motor-clutch model of cell migration, mesenchymal glioma cells are more spread, generate larger traction forces, and migrate faster in brain tissue compared to proneural cells. Despite their rapid migration and comparable proliferation rates in vitro, mice with mesenchymal tumors survive longer than those with proneural tumors. This improved survival correlated with an immune response in the mesenchymal tumors, including T cell-mediated. Consistently, inducing mesenchymal tumors in immunodeficient mice resulted in shorter survival supporting a protective immune role in mesenchymal tumors. Thus, mesenchymal tumors have aggressive migration, but are immunologically ‘hot’ which suppresses net proliferation. These two features counteract each other and may explain the lack of a strong survival difference between subtypes clinically, while also opening up new opportunities for subtype-specific therapies. Significant Statement This study highlights new mechanical and immunological insights into glioblastoma molecular subtypes using an integrated modeling-genome engineering strategy, which can potentially facilitate glioblastoma subtype-specific therapeutic strategies.
Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma
Parney, Ian F. , Anderson, S. Keith , Gustafson, Michael P. , Steinmetz, Susan, Peterson, Timothy E., Kroneman, Trynda, Buckner, Jan C. , Solseth, Mary L., Dietz, Allan B. , Kroneman, Trynda N, Raghunathan, Aditya , Buckner, Jan C , Solseth, Mary, Parney, Ian F , Dietz, Allan B , Anderson, S Keith , Steinmetz, Susan, Raghunathan, Aditya , O’Neill, Brian Patrick

Mayo Clinic

Neuro-Oncology Advances | June 24, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac089 | PMID 35967100 Get It

Abstract Background Glioblastoma (GBM) has poor prognosis despite aggressive treatment. Dendritic cell (DC) vaccines are promising, but widespread clinical use has not been achieved, possibly reflecting manufacturing issues of antigen choice and DC potency. We previously optimized vaccine manufacture utilizing allogeneic human GBM tumor cell lysate and potent, mature autologous DCs. Here, we report a phase I study using this optimized DC vaccine in combination with standard therapy. Methods Following surgical resection and radiation with concurrent temozolomide (TMZ), newly diagnosed adult GBM patients received intradermal DC vaccines plus TMZ. Primary endpoints were safety and feasibility. Immune and treatment responses were recorded. Results Twenty-one patients were enrolled in this study. One progressed between leukapheresis and vaccine manufacture. Twenty patients received treatment per protocol. Vaccine doses (≥15) were generated following a single leukapheresis for each patient. No dose-limiting vaccine toxicities were encountered. One patient had symptomatic, histologically proven pseudoprogression. Median progression-free survival was 9.7 months. Median overall survival was 19 months. Overall survival was 25% at 2 years and 10% at 4 years. One patient remains progression-free 5 years after enrollment. Specific CD8 T-cell responses for the tumor-associated antigen gp100 were seen post-vaccination. Patients entered the trial with a leukocyte deficit compared to healthy donors which partly normalized over the course of therapy. Conclusions This vaccine platform is safe and highly feasible in combination with standard therapy for newly diagnosed patients. Imaging, histological, survival, and immunological data suggest a positive biological response to therapy that warrants further investigation.
134. Dispose With Dish Soap: A Simple And Convenient Method to Increase Proper Opioid Disposal in Postoperative Pediatric Patients
Keane, Alexandra M., Payne, Rachael M. , Cooke, Samantha, Zubovic, Ema , Snyder‐Warwick, Alison K. , Larson, Ellen L. , Patel, Kamlesh B. , Mackinnon, Susan E.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | June 23, 2022 | Volume: 10 | Issue: 6S | Pages: 88-88

10.1097/01.gox.0000842852.33414.99 Get It